Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
Clasificación en acciones #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
Precio por acción
$4.64
Última sincronización: 2022-09-12
Capitalización bursátil
$293.43M
Cambio (1 día)
0.87%
Cambio (1 año)
0.00%
País
US
Comercio Adagio Therapeutics, Inc. (ADGI)

Categoría

Historial del precio de la acción de Adagio Therapeutics, Inc. (ADGI)
Precio más alto de cierre: $4.63 el 2022-09-01

Precio más bajo de cierre: $27.68 el 2021-08-01
Historial del precio de la acción de Adagio Therapeutics, Inc. desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2022 -78.16%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$121.61 -10.47%
AU
$748.60 6.90%
CH